RCS - N4 Pharma PLC - Investor Event and Presentation

N4 PharmaAnnouncement

11/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250911:nRSK8428Ya&default-theme=true

RNS Number : 8428Y  N4 Pharma PLC  11 September 2025

 

11 September 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Investor Event and Presentation

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce that the Company will be presenting at the
ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo
Hotel, Brewery Place, Leeds, LS10 1NE. Event registration opens at 4.30 pm and
presentations commence at 5.00 pm.

 

Nigel Theobald, Chief Executive Officer, will be presenting on the Company's
ongoing development of Nuvec® as a delivery system for RNA therapeutics.

For further information on the ShareSoc Growth Company Seminar and
registration, please visit the event
website: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/
(https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/)

A link to N4 Pharma's presentation will be made available on the Company
website following the event. No new material information will be disclosed at
this event.

- Ends -

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://n4pharma.com/link/eY2Bqr (https://n4pharma.com/link/eY2Bqr) .
 Submit your questions directly to the management team via the N4 Pharma

 Investor Hub
 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

 

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFLEATIILIE